These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38059478)

  • 21. Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell carcinoma.
    Bila M; Franken A; Van Dessel J; Garip M; Meulemans J; Willaert R; Hoeben A; Vander Poorten V; Clement PM
    Oral Oncol; 2024 Feb; 149():106664. PubMed ID: 38113661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 23. Association of Nutritional Indices With Adverse Effects and Time-to-Treatment-Failure in Triple Therapy for Lung Cancer.
    Hashino Y; Matushita T; Hatsuyama T; Wakamoto A; Goto K; Hoshi T; Iwayama K; Ohtaki K; Toda T; Sato H
    In Vivo; 2024; 38(2):864-872. PubMed ID: 38418111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does the geriatric nutrition risk index predict the prognosis of patients with oral squamous cell carcinoma?
    Yamagata K; Fukuzawa S; Uchida F; Terada K; Ishibashi-Kanno N; Bukawa H
    Br J Oral Maxillofac Surg; 2022 May; 60(4):475-481. PubMed ID: 35086741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SEC61G overexpression and DNA amplification correlates with prognosis and immune cell infiltration in head and neck squamous cell carcinoma.
    Lu T; Chen Y; Gong X; Guo Q; Lin C; Luo Q; Tu Z; Pan J; Li J
    Cancer Med; 2021 Nov; 10(21):7847-7862. PubMed ID: 34590792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
    Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
    Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors.
    Liu C; Zhao H; Zhang R; Guo Z; Wang P; Qu Z
    Oncol Lett; 2023 Oct; 26(4):437. PubMed ID: 37664652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advanced lung cancer inflammation index and its prognostic value in HPV-negative head and neck squamous cell carcinoma: a multicentre study.
    Gaudioso P; Borsetto D; Tirelli G; Tofanelli M; Cragnolini F; Menegaldo A; Fabbris C; Molteni G; Marchioni D; Nicolai P; Bossi P; Ciorba A; Pelucchi S; Bianchini C; Mauramati S; Benazzo M; Giacomarra V; Di Carlo R; Sethi M; Polesel J; Fussey J; Boscolo-Rizzo P
    Support Care Cancer; 2021 Aug; 29(8):4683-4691. PubMed ID: 33515105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.
    Dang S; Zhang S; Zhao J; Li X; Li W
    Cancer Med; 2023 Oct; 12(20):20277-20286. PubMed ID: 37814950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation and malnutrition as markers of poor outcomes in head and neck cancer patients treated with nivolumab.
    Arihara Y; Takada K; Murase K; Kawamura K; Kakiuchi A; Kurose M; Sasaki T; Ogi K; Yamazaki M; Miyazaki A; Kato J; Takano K
    Acta Otolaryngol; 2023 Aug; 143(8):714-720. PubMed ID: 37537940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
    Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C
    Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Geriatric Nutritional Risk Index as a Prognostic Factor in Patients with Advanced Head and Neck Cancer.
    Nakayama M; Gosho M; Adachi M; Ii R; Matsumoto S; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
    Laryngoscope; 2021 Jan; 131(1):E151-E156. PubMed ID: 32083731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The predictive and prognostic value of weight loss and body composition prior to and during immune checkpoint inhibition in recurrent or metastatic head and neck cancer patients.
    Willemsen ACH; De Moor N; Van Dessel J; Baijens LWJ; Bila M; Hauben E; van den Hout MFCM; Vander Poorten V; Hoeben A; Clement PM; Schols AMWJ
    Cancer Med; 2023 Apr; 12(7):7699-7712. PubMed ID: 36484469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy.
    Qiu J; Yang J; Yu Y; Wang Z; Lin H; Ke D; Zheng H; Li J; Yao Q
    BMC Cancer; 2023 Jun; 23(1):597. PubMed ID: 37380982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.
    Nenclares P; Gunn L; Soliman H; Bover M; Trinh A; Leslie I; Wong KH; Melcher A; Newbold K; Nutting CM; Ap Dafydd D; Bhide SA; Harrington K
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Geriatric Nutritional Risk Index and Prognostic Nutritional Index Predict the Overall Survival of Advanced Non-Small Cell Lung Cancer Patients.
    Matsuura S; Morikawa K; Ito Y; Kubota T; Ichijo K; Mochizuki E; Akiyama N; Uehara M; Harada M; Tsukui M; Koshimizu N
    Nutr Cancer; 2022; 74(5):1606-1613. PubMed ID: 34431441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Impact of Prognostic Nutritional Index in Patients with Cancer Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Xu XT; Qian Y; Tian MX; Ding CC; Guo H; Tang J; Pi GL; Wu Y; Dai Z; Jin X
    Nutr Cancer; 2023; 75(6):1413-1426. PubMed ID: 37140894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint Inhibitors.
    Hobday SB; Brody RM; Kriegsman B; Basu D; Newman J; Cohen RB; Lukens JN; Singh A; D'Avella CA; Sun L
    JAMA Otolaryngol Head Neck Surg; 2022 Oct; 148(10):918-926. PubMed ID: 35980666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.